AR053358A1 - Inhibidores de adn - pk - Google Patents

Inhibidores de adn - pk

Info

Publication number
AR053358A1
AR053358A1 ARP060101480A ARP060101480A AR053358A1 AR 053358 A1 AR053358 A1 AR 053358A1 AR P060101480 A ARP060101480 A AR P060101480A AR P060101480 A ARP060101480 A AR P060101480A AR 053358 A1 AR053358 A1 AR 053358A1
Authority
AR
Argentina
Prior art keywords
group
optionally substituted
alkyl
nitrogen atom
attached
Prior art date
Application number
ARP060101480A
Other languages
English (en)
Inventor
Murr Desage-El
Smith
Martin
Keith Allan Menear
Marc Geoffrey Hummersone
Xiao Ling Cockcroft
Frigerio
John Griffinroger
Bernard Thomas Golding
Ian Robert Hardcastle
David Richard Newell
Hilary Alan Calvert
Nicola Jane Curtin
Saravanan
Original Assignee
Cancer Rec Tech Ltd
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0507831A external-priority patent/GB0507831D0/en
Application filed by Cancer Rec Tech Ltd, Kudos Pharm Ltd filed Critical Cancer Rec Tech Ltd
Publication of AR053358A1 publication Critical patent/AR053358A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) e isomeros, sales solvatos, formas químicamente protegidas y prodrogas del mismo, donde: A, B, y D se seleccionan respectivamente entre el grupo que consiste en: (i) CH, NH. C: (ii) CH, N, N: y (iii) CH, O, C; las líneas punteadas representan dos dobles enlaces en las ubicaciones apropiadas; Rn1 y Rn2 se seleccionan en forma independiente entre hidrogeno, un grupo C1-7 alquilo, C3-20 heterociclilo, o C5-20 arilo opcionalmente sustituido, o pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo; si A, B, D se seleccionan entre los grupos (i), (ii) mencionados, Z se selecciona entre el grupo que consiste en S, O, C(=O), CH2 y NH; y si A, B, O, C(=O9, CH2 y NH; R4 se selecciona entre el grupo que consiste en H; OH, NO2, NH2, y Q-Y-X donde Q es -NH-C(=O)- o O-; Y es un grupo C1-5 alquileno opcionalmente sustituido; X se selecciona entre SRs1 o NRn3Rn4, donde, Rs1, o Rn3 y Rn4 se seleccionan en forma independiente entre hidrogeno, grupos C1-7 alquilo, C5-20 arilo o C3-20 heterociclilo opcionalmente sustituidos, o Rn3 y Rn4 pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo; si Q es -O-, X puede seleccionarse además entre -C(=O)-NRn5Rn6, donde Rn5 y Rn6 pueden formar juntos, junto con el átomo de nitrogeno al cual están unidos, un anillo heterocíclico opcionalmente sustituido con entre 4 y 8 átomos del anillo y si Q es-NH-C(=O)-, -Y-X puede seleccionarse además entre C1-7 alquilo, con la condicion de que si A; B: D representan el grupo (iii) y Rn1 y Rn2 junto con el átomo de carbono al cual están unidos forman un grupo morfolino, R4 no puede ser H.
ARP060101480A 2005-04-15 2006-04-12 Inhibidores de adn - pk AR053358A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67183005P 2005-04-15 2005-04-15
US67188605P 2005-04-15 2005-04-15
GB0507831A GB0507831D0 (en) 2005-04-18 2005-04-18 DNA-PK inhibitors
US69606405P 2005-07-01 2005-07-01
US71890405P 2005-09-20 2005-09-20

Publications (1)

Publication Number Publication Date
AR053358A1 true AR053358A1 (es) 2007-05-02

Family

ID=36579227

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060101480A AR053358A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn - pk
ARP060101479A AR054438A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn -pk

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060101479A AR054438A1 (es) 2005-04-15 2006-04-12 Inhibidores de adn -pk

Country Status (13)

Country Link
US (2) US7696203B2 (es)
EP (2) EP1869021A1 (es)
JP (2) JP2008535902A (es)
KR (1) KR20080002963A (es)
AR (2) AR053358A1 (es)
AU (1) AU2006235731A1 (es)
CA (1) CA2603637A1 (es)
IL (1) IL186445A0 (es)
MX (1) MX2007012696A (es)
NO (1) NO20075809L (es)
TW (2) TW200720271A (es)
UY (1) UY29479A1 (es)
WO (2) WO2006109081A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7429660B2 (en) * 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
AU2005286329A1 (en) 2004-09-20 2006-03-30 Cancer Research Technology Limited DNA-PK inhibitors
EP1848712A1 (en) * 2005-02-09 2007-10-31 Kudos Pharmaceuticals Ltd Atm inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
EP2198710A1 (de) 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
WO2010136778A1 (en) * 2009-05-29 2010-12-02 Kudos Pharmaceuticals Limited Dibenzothiophene derivatives as dna- pk inhibitors
FR2951170B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
AR077628A1 (es) 2009-07-02 2011-09-14 Sanofi Aventis Derivados de 6-(morfolin-4-il)-pirimidin-4(3h)-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fosforilacion de akt(pkb)
MA33501B1 (fr) 2009-07-02 2012-08-01 Sanofi Sa Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947548B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
FR2947551B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
PT2448939T (pt) 2009-07-02 2017-06-12 Sanofi Sa Derivados de 2,3-dihidro-1h-imidazo{1,2-a}pirimidin-5-ona, sua preparação e sua utilização farmacêutica
AU2010267815B2 (en) * 2009-07-02 2015-07-16 Sanofi Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof
FR2947550B1 (fr) * 2009-07-02 2012-05-18 Sanofi Aventis Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb)
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
KR101849889B1 (ko) 2010-04-15 2018-04-17 쓰리엠 이노베이티브 프로퍼티즈 캄파니 광학적 활성 영역 및 광학적 불활성 영역을 포함하는 재귀반사성 물품
US20130109687A1 (en) * 2010-04-30 2013-05-02 Gary J. Nabel Methods of treating hiv infection: inhibition of dna dependent protein kinase
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
ES2531465T3 (es) 2010-12-23 2015-03-16 Sanofi Derivados de pirimidinona, su preparación y su utilización farmacéutica
EP2658844B1 (fr) 2010-12-28 2016-10-26 Sanofi Nouveaux derives de pyrimidines, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
UY34013A (es) * 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
DK3459942T3 (da) 2012-04-24 2021-03-08 Vertex Pharma DNA-PK-hæmmere
CA2876539A1 (en) * 2012-06-15 2013-12-19 Basf Se Multicomponent crystals comprising dasatinib and selected co-crystal formers
FR2992316A1 (fr) 2012-06-22 2013-12-27 Sanofi Sa Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr) 2012-06-22 2015-10-16 Sanofi Sa Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
EP3985003B1 (en) 2013-03-12 2023-08-09 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2016086261A1 (en) * 2014-12-02 2016-06-09 Prana Biotechnology Limited 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
MX2019003317A (es) 2016-09-27 2019-08-05 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
CN109232476B (zh) * 2018-11-06 2020-06-26 常州大学 一种制备n-苯基-3-吗啡啉丙酰胺的方法
WO2021184014A1 (en) * 2020-03-13 2021-09-16 Arizona Board Of Regetns On Behalf Of The University Of Arizona Stable reactive compositions for bioconjugation, probes, and protein labeling

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (es) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
AU634994B2 (en) 1988-12-21 1993-03-11 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
ES2106783T3 (es) 1990-06-20 1997-11-16 Upjohn Co 1-benzopiran-4-onas y 2-amino-1,3-benzoxacin-4-onas antiarterosclerosis y antitromboticas.
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
JPH05501886A (ja) 1990-06-29 1993-04-08 ジ・アップジョン・カンパニー 抗アテローム性動脈硬化症性および抗血栓性２―アミノ―６―フェニル―４ｈ―ピラン―４―オン類
EP0610519B1 (en) 1992-09-02 1999-12-01 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
EP0695547B1 (en) 1993-04-09 2001-08-08 Toyama Chemical Co., Ltd. Immunomodulator, cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1997018323A2 (en) 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
CA2292540A1 (en) 1997-06-06 1998-12-10 Jann N. Sarkaria Screening for phosphatidylinositol related-kinase inhibitors
WO1998056391A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
DE60128655T2 (de) * 2000-01-24 2008-02-07 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
US7179912B2 (en) 2000-09-01 2007-02-20 Icos Corporation Materials and methods to potentiate cancer treatment
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
WO2003035618A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
AU2002357667A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
DK1485377T5 (da) 2002-02-25 2010-12-06 Kudos Pharm Ltd Pyranoner egnede som ATM-inhibitorer
US7196085B2 (en) 2002-04-30 2007-03-27 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7429660B2 (en) 2003-08-13 2008-09-30 Kudos Pharmaceuticals Limited ATM inhibitors
AU2005286329A1 (en) 2004-09-20 2006-03-30 Cancer Research Technology Limited DNA-PK inhibitors
EP1848712A1 (en) 2005-02-09 2007-10-31 Kudos Pharmaceuticals Ltd Atm inhibitors
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
MX2007012696A (es) 2008-03-14
TW200720271A (en) 2007-06-01
EP1869021A1 (en) 2007-12-26
KR20080002963A (ko) 2008-01-04
IL186445A0 (en) 2008-01-20
WO2006109084A1 (en) 2006-10-19
AU2006235731A1 (en) 2006-10-19
TW200720274A (en) 2007-06-01
NO20075809L (no) 2007-12-27
EP1869040A1 (en) 2007-12-26
JP2008535903A (ja) 2008-09-04
US20060264427A1 (en) 2006-11-23
JP2008535902A (ja) 2008-09-04
UY29479A1 (es) 2006-11-30
CA2603637A1 (en) 2006-10-19
US20060264623A1 (en) 2006-11-23
US7696203B2 (en) 2010-04-13
WO2006109081A1 (en) 2006-10-19
AR054438A1 (es) 2007-06-27

Similar Documents

Publication Publication Date Title
AR053358A1 (es) Inhibidores de adn - pk
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
NO20074057L (no) 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer
AR053149A1 (es) Uso de compuestos de diosmetina para la obtencion de composiciones farmaceuticas destinadas a la prevencion y/o tratamiento de patologias tromboticas y patologias que conlleven el riesgo de producir trombosis
NO20071873L (no) DNA-PK inhibotorer.
UY31014A1 (es) Derivados de ftalazinona
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
AR051326A1 (es) Pirazolobenzodiazepinas disustituidas
AR048749A1 (es) 4-(4-trifluorometilpirazolil)-pirimidinas sustituidas
TW200634017A (en) Bi-and tricyclic substituted phenyl methanones
RS53061B (en) INHIBITORI PROTEIN KINAZE
TW200640462A (en) Compounds
SV2009003152A (es) Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
TW200621786A (en) Condensed pyrazole derivatives, their preparation and application in therapeutics
MA32731B1 (fr) Céphalosporine possédant un groupe catéchol
ES2603931T3 (es) Compuestos de triazolo
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
CO5540343A2 (es) Derivados de furano y tiofeno que activan receptores activados por el proliferador de la peroxisoma humana
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
AR054814A1 (es) Derivados de piridazina
AR049784A1 (es) Derivados sustituidos de morfolina y tiomorfolina
AR057626A1 (es) Derivados de pirido pirazo y pirimido- pirimidina y su uso como inhibidores de mtor
CR9066A (es) Nuevos derivados de aminopirimidina que tiene accion inhibitoria selectiva de la aurora a

Legal Events

Date Code Title Description
FA Abandonment or withdrawal